colchicine / Generic mfg. - LARVOL DELTA

Henoch-Schönlein purpura induced by sitagliptin: a case report (AAD 2026) - "The patient was then treated with celecoxib, colchicine, and cefadroxil for wound infection. To our knowledge, this is the first case of sitagliptin-induced HSP and the third case of sitagliptin-induced LCV documented in the literature.3,4 Overall, this case highlights a new potential association of DPP-4 inhibitors with HSP, which may have systemic consequences."

Case report • Clinical • Diabetes • Infectious Disease • Metabolic Disorders • Respiratory Diseases • Type 2 Diabetes Mellitus • Vasculitis

Effect of Colchicine Use and Usual Care Alone on the Rate of Progression to Chronic Kidney Disease and Mortality in Patients with Heat-Related Injury. (PubMed, Healthcare (Basel)) - "Colchicine use following HRI was associated with favorable long-term renal outcomes, including reduced risks of CKD progression and dialysis. Although causal inference cannot be established due to the observational design, these findings suggest a potential renoprotective association of colchicine in patients with HRI."

Journal • Acute Kidney Injury • Chronic Kidney Disease • Inflammation • Nephrology • Renal Disease

Association Between Vitamin D, Vitamin B12 and Folate Levels and Persistent Subclinical Inflammation in Pediatric Familial Mediterranean Fever. (PubMed, Children (Basel)) - " Children aged 2-18 years with an FMF diagnosis of more than two years, receiving regular colchicine therapy, and attack-free for at least two months were included...Comparison between patients with and without subclinical inflammation showed no significant differences in micronutrient levels. Although micronutrients have been reported to play immunomodulatory roles, we did not observe significant association between vitamin levels and subclinical inflammation in pediatric FMF patients in our study."

Journal • Genetic Disorders • Infectious Disease • Inflammation • Nephrology • Pediatrics • Renal Disease

Discovery of quinoxaline-chalcone derivatives as covalent colchicine binding site inhibitors for breast and fibrosarcoma treatment. (PubMed, Eur J Med Chem) - "Meanwhile, molecular docking result suggested 10v occupied colchicine binding site and formed covalent binding with β-Cys239. Finally, in vivo study indicated 10v showed better in vivo antitumor efficacy than paclitaxel with acceptable safety."

Journal • Fibrosarcoma • Oncology • Sarcoma • Solid Tumor

Effusive constrictive pericarditis and an anterior mediastinal mass: a case report. (PubMed, Eur Heart J Case Rep) - "The patient was started on colchicine and transferred to a tertiary care hospital for further management...Biopsy, taken from the anterior mediastinal mass, confirmed the diagnosis of primary mediastinal large B-cell lymphoma, and he was started on of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy. Effusive-constrictive pericarditis is an uncommon but critical manifestation of primary mediastinal large B-cell lymphoma. Combination of large pericardial effusion with constrictive features and persistent non-compliant pericardium with elevated intracardiac pressures after pericardiocentesis are its hallmarks."

Journal • Anorexia • B Cell Lymphoma • Cardiovascular • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma • Respiratory Diseases

In-silico studies on effective phytochemicals of Crocus sativus, Ocimum tenuiflorum and its modifications targeting NIPAH virus. (PubMed, In Silico Pharmacol) - "We determined from these screenings that the compounds with the highest binding affinity values were colchicine, cadinene and its derivatives - C4, C6, and C8 which were found to be better than the popular reference drug ribavirin. In addition to the docking and MD testing, additional drug-likeness and toxicity tests have identified compounds like cadinene, colchicine, and its derivatives (C4 of colchicine derivative, and C6 and C8 of cadinene derivatives) as effective against the Nipah virus. The online version contains supplementary material available at 10.1007/s40203-026-00611-w."

Journal

Reverse Takotsubo Syndrome Triggered by COVID-19-Associated Cytokine Storm: Unveiling a Novel Pattern of Myocardial Dysfunction in SARS-CoV-2 Infection. (PubMed, Am J Case Rep) - "She received colchicine and spironolactone as anti-inflammatory therapy. Clinicians should consider rTTC in COVID-19 patients presenting with atypical chest pain and modest biomarker elevation. Early echocardiography and targeted anti-inflammatory therapy may facilitate diagnosis and promote full recovery."

Journal • Cardiomyopathy • Cardiovascular • Genetic Disorders • Heart Failure • Hypertension • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Novel Coronavirus Disease • Obesity • Pain • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology

Effect of colchicine for secondary prevention of cardiovascular diseases in individuals with diabetes: A meta-analysis of randomized trials. (PubMed, Diab Vasc Dis Res) - "Colchicine did not increase adverse events: composite events RR 0.81 (95% CI 0.68-0.96; p = 0.02), gastrointestinal events RR 1.09 (95% CI 0.98-1.20, p = 0.12), or musculoskeletal events RR 0.77 (95% CI 0.43-1.38, p = 0.39). Benefits were observed with 0.5 mg daily over a median 28.6 months.ConclusionColchicine is associated with a reduction in major cardiovascular events in individuals with diabetes, with consistent long-term benefit at low doses without an increase in adverse effects."

Clinical • Journal • Retrospective data • Review • Cardiovascular • Diabetes • Metabolic Disorders • Musculoskeletal Diseases

Anti-inflammatory therapies to prevent cardiovascular events: systematic review and network meta-analysis of randomised controlled trials. (PubMed, Front Cardiovasc Med) - "In patients with stable CAD, colchicine and corticosteroids were associated with a reduction in MACE, although these findings were informed largely by indirect comparisons. Identifier CRD42022303289."

Journal • Retrospective data • Review • Acute Coronary Syndrome • Cardiovascular • Coronary Artery Disease

Colchicine Alleviates Non-Atherosclerotic Vascular Aging by Targeting Endothelial Dysfunction and Inflammatory Status. (PubMed, J Inflamm Res) - "Chronic colchicine significantly (p<0.01) lowered PWV, preserved elastin architecture, and improved endothelium-dependent relaxation, while sodium-nitroprusside responses and systemic cytokine levels remained unchanged. Chronic colchicine treatment preserves endothelial function and vascular elastin structure and reduces arterial stiffness in a DNA-damage-driven model of non-atherosclerotic vascular aging. These findings highlight colchicine's pleiotropic vascular benefits beyond anti-inflammation, supporting its potential repurposing for primary prevention in vascular aging and cardiovascular health or the development of colchicine-mimicking drugs with greater selectivity and improved safety profiles."

Journal • Atherosclerosis • Cardiovascular • Inflammation • ERCC1

EULAR recommendations for the management of Behçet's syndrome: 2025 update. (PubMed, Ann Rheum Dis) - "These recommendations, which were updated based on new evidence and expert opinion, provide guidance for all stakeholders involved in the management of patients with Behçet's syndrome to improve the quality of care of these patients."

Journal • Oncology • Ophthalmology • Rare Diseases • Rheumatology

Colchicine-Responsive Dacron Hypersensitivity After Bentall Procedure: A Rare Trigger of Diffuse Coronary Artery Disease. (PubMed, JACC Case Rep) - "Diffuse fibrotic thickening throughout the coronary arteries after a Bentall procedure may be caused by eosinophilic inflammation. Colchicine and oral corticosteroids may suppress the eosinophilic inflammation induced by the Dacron graft in distant organs. Eosinophil count may be monitored for the therapeutic response of long-term colchicine usage."

Journal • Acute Coronary Syndrome • Cardiovascular • Coronary Artery Disease • Fibrosis • Immunology • Inflammation

Anifrolumab in Refractory Oral Manifestations in Systemic Lupus Erythematosus: A Case Report and Literature Review. (PubMed, Biologics) - "We report the case of a 39-year-old woman with SLE who developed severe, refractory tongue ulcers and glossodynia persisting for three years, unresponsive to hydroxychloroquine (HCQ), azathioprine (AZA), colchicine, methotrexate (MTX), and glucocorticoids (GC). Belimumab was discontinued due to gastrointestinal intolerance and lack of efficacy on oral lesions...While conventional immunosuppressants such as azathioprine, methotrexate, and mycophenolate mofetil remain options, their efficacy for isolated oral lesions is limited...The key learning point is that refractory tongue involvement may represent a dominant and treatment-resistant manifestation of SLE, yet it can respond to targeted biologic therapy such as anifrolumab and our report adds to this growing body of evidence. Prospective comparative studies and registry analyses are required to define anifrolumab's effectiveness specifically for refractory oral manifestations and to compare outcomes with other..."

Journal • Immunology • Inflammatory Arthritis • Lupus • Rheumatology • Systemic Lupus Erythematosus

CRISPR-CAS9 KNOCKOUTS OF P2RY12 FROM IPSCS DERIVED FROM PARKINSON'S PATIENTS WITH HIGH POLYGENIC RISK SCORE (ADPD 2026) - "Identity was proved by single tandem repeats (STR) of iPSCs and patient blood samples, and normal karyotype was proved by incubation 24h with Colchicine and metaphase preparations stained using Wright's stain to obtain G-banded chromosomes. Sanger sequencing confirmed indel mutations. P2RY12 KOs has successfully been made of four PD iPSC-lines with high PD PRS using CRISPR-Cas9 without affecting overlapping MED12L."

Clinical • CNS Disorders • Movement Disorders • Parkinson's Disease • NANOG • POU5F1 • SOX2

Rivaroxaban, colchicine and famotidine/loratadine with integrated clinical care for Long COVID, a multi-site, open-label randomised controlled trial (ESCMID Global 2026) - No abstract available

Clinical • Late-breaking abstract • Novel Coronavirus Disease

Mechanistic Clinical Trial of Colchicine in Patients With Peripheral Artery Disease (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: University of Pennsylvania | Trial completion date: Jan 2026 ➔ Apr 2026 | Trial primary completion date: Jan 2026 ➔ Apr 2026

Trial completion date • Trial primary completion date • Cardiovascular • Peripheral Arterial Disease

In vitro pharmacological modulation of NKG2D expression in immune cells from Behçet syndrome patients. (PubMed, Clin Exp Immunol) - "Drugs used in the management of BS reduced NKG2D expression, potentially decreasing the activation of cytotoxic cells. Immune cells from BS patients responded differently to dexamethasone and colchicine compared to those from CTR."

Journal • Preclinical • IL15 • NKG2D

Can Colchicine Be a Therapeutic Option for Patients With Ankylosing Spondylitis? (PubMed, Int J Rheum Dis) - No abstract available

Journal • Ankylosing Spondylitis • Immunology • Inflammatory Arthritis • Rheumatology • Seronegative Spondyloarthropathies

A personalized therapeutic approach for liver cancers expressing the African-centric P47S Variant of TP53. (PubMed, Mol Cancer Res) - "We identify the microtubule targeting agents lexibulin, colchicine, and combretastatin A-4 as three compounds that bind to the colchicine-binding pocket of the a/b tubulin dimer, and which show increased efficacy in a P47S liver cancer cell line compared to parental cells with WT p53. We find evidence for an unusual mechanism underlying this increased efficacy: our data indicate that the P47S variant shows increased ability to bind to the peptidyl-prolyl isomerase PIN1; this leads to decreased PIN1-cyclin D1 complexes in P47S cells, along with increased cell cycle arrest in response to lexibulin. IMPLICATIONS: These findings support the growing literature that particular mutant forms of TP53 may have specific therapeutic vulnerabilities that can be targetable; improved understanding of these unique vulnerabilities can lead to improved understanding of p53 function."

Journal • Liver Cancer • Oncology • Solid Tumor • CCND1 • TP53

EVOLOCUMAB-ASSOCIATED PERICARDITIS WITH CARDIAC TAMPONADE: A DIAGNOSIS OF EXCLUSION (ACC 2026) - "He was discharged on colchicine and indomethacin. Though exceedingly rare, pericardial effusion and tamponade may represent adverse effects of PCSK9 inhibitors. Clinicians should consider drug-induced pericarditis when other causes are excluded, and broader pharmacovigilance is warranted as use of these therapies expands."

Cardiovascular • Immunology

WHEN IMAGING THE ABDOMEN REVEALS THE HEART: MALIGNANT PERICARDIAL EFFUSION IN VULVAR CANCER (ACC 2026) - "Case: A 51-year-old woman with vulvar SCC treated with radiation and cisplatin presented with dyspnea...She was discharged on colchicine and ibuprofen with plans for pembrolizumab, paclitaxel, and carboplatin, but before initiation died from acute pulmonary embolism... This case represents the first cytology-proven malignant pericardial effusion from vulvar SCC, underscoring that even rare cancers may reach the heart."

Gynecologic Cancers • Kidney Cancer • Oncology • Pulmonary Disease • Pulmonary Embolism • Renal Cell Carcinoma • Respiratory Diseases • Solid Tumor • Squamous Cell Carcinoma • Vulvar Cancer • TP63

Pyoderma gangrenosum: a case report highlighting the importance of early diagnosis and treatment. (PubMed, Int J Surg Case Rep) - "He was transitioned to oral prednisone and later to oral cyclosporine, achieving complete re-epithelialization by POD32. Colchicine was initiated for maintenance therapy...Early clinical recognition and prompt immunosuppression are central to management. Serial patient-acquired photographs can support monitoring and guide treatment decisions."

Journal • Dermatology • Gastroenterology • Infectious Disease • Inflammation • Pyoderma Gangrenosum • CRP • PLCG2

Assessment of Liver Fibrosis in Familial Mediterranean Fever Using Shear Wave Elastography: Role of Cumulative Colchicine Exposure, Metabolic and Genetic Factors (EULAR 2026) - No abstract available

Fibrosis • Genetic Disorders • Hepatology • Immunology • Liver Cirrhosis

Impact of MEFV Mutations on the Efficacy and Safety of Colchicine and Interleukin-1 Inhibitors in Familial Mediterranean Fever: A Real-World Cohort Study (EULAR 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Genetic Disorders

Colchicine Use Reduces Major Cardiovascular Events in Behçet's Disease (EULAR 2026) - No abstract available

Cardiovascular • Rare Diseases